(BSNS WIRE)
NVID to Receive U.S. Patent on Revolutionary Ionic Silver Microbial Technology
Business Editors
CLEARWATER, Fla.--(BUSINESS WIRE)--Aug. 10, 2000--NVID
International, Inc. (Pink Sheets:NVID) today announced the U.S. Patent
and Trademark Office has granted Official Notice of Allowance to a
pending utility patent application regarding NVID's Axen microbial
technology. It is expected the U.S. Patent and Trademark Office will
issue the U.S. Letters Patent within the next three to six months.
The U.S. Letters Patent covers one of multiple inventive aspects
of NVID's Axen microbial technology. NVID intends to file further U.S.
Divisional patent applications to cover the remaining inventive
concepts of NVID's Axen microbial technology.
Axen is NVID's non-toxic antibacterial technology that uses the
biocidal properties of stabilized ionic silver to kill bacteria,
viruses and fungi. Axen does not include the use of traditional
disinfectants such as quaternary ammonium salts, phenols,
glutaraldehyde, chlorine or bromine compounds. The Axen formulations
have been designed to compete, and/or replace these products while
eliminating the associated environmental hazards. The disinfection
efficacy of Axen has been well documented by independent testing
laboratories. Axen eliminates the following test organism strains all
within one minute and 99.9999% efficacy (complete kill).
Pseudomonas aeruginosa ATCC 15442
Staphylococcus aureus ATCC 6538
Salmonella cholerasuis ATCC 10708
E. Coli ATCC 0157:H7
Listeria monocytogenes ATCC 11543
Enterococcus faecium ATCC 11543
Rhinovirus (common colds)
Rotavirus (infectious diarrhea)
Vancomycin-resistant-enterococci (VRE)
Antibiotic-resistant bacteria
Target markets include: hospital and nursing home water systems,
point-of-use/point-of-entry; municipal, commercial and residential
drinking water, FDA compliant consumer products, pools and spas,
cisterns/wells, dental unit waterlines, veterinary, horticulture,
agriculture and food processing applications.
"The official U.S. allowance from the U.S. Patent and Trademark
Office now gives NVID a greater probability of success for patenting
Axen in foreign countries," commented David J. Larson President of
NVID. "This strengthens and validates NVID's market position in
regards to the inventiveness and potential marketability of the Axen
microbial technology. Thanks to all of the NVID shareholders who have
waited patiently for this intellectual property to come to fruition.
Additionally, the driving force behind the Axen project has been Mr.
Andrew B. Arata of Lake City, Florida, Axen Inventor of Record on
behalf of NVID. Mr. Arata has never wavered from day-one in regards to
his commitment and vision for this project."
NVID has filed for patent coverage outside the U.S. in national
and regional member countries of the Patent Cooperation Treaty. In
December of 1999 the preliminary International Examining Authority of
the World Intellectual Property Organization issued a First Written
Opinion regarding the NVID Axen patent application. The First Written
Opinion stated that the invention as set forth in claims 26-29 has
(1) novelty, (2) inventive step, and (3) industrial applicability.
Accordingly, the invention as set forth in claims 26-29 appears to
meet the patentability criteria of PCT article 33(2) - 33(4) based on
the standards of the International Examination Authority. The
application was published by the World Intellectual Property
Organization on April 22, 1999 under publication Number WO 99/18790,
and is available for public inspection.
Patent applications have been filed to date in the following
countries and regions based on the subject PCT patent application.
-0-
*T
Nations: Australia, Brazil, Canada, China, Japan, Mexico and
New Zealand.
Regions: ARIPO Patent: Ghana, Gambia, Kenya, Lesotho, Malawi,
Sudan, Swaziland, Uganda and Zimbabwe.
Eurasian Patent: Armenia, Azerbaijan, Belarus,
Kyrgystan, Republic of Moldova, Russian Federation,
Tajikistan, and Turkmenistan.
European Patent: Austria, Belgium, Switzerland,
Liechtenstein, Germany, Denmark, Spain, Finland,
France, United Kingdom, Greece, Ireland, Italy,
Luxembourg, Monaco, Netherlands, Portugal, and Sweden.
OAPI Patent: Burkina, Faso, Benin, Central African
Republic, Congo, Guinea, Bissau, Coted'Ivoire,
Cameroon, Gabon, Guinea, Mauritania, Niger, Senegal,
Chad and Togo.
*T
About NVID International, Inc.
NVID International, Inc. based in Clearwater, Florida,
manufactures and markets patented and patent-pending proprietary
ionization disinfection technologies that substantially reduce or
replace traditional disinfectants such as chlorine or bromine.
The matters discussed in this news release are forward-looking
statements with respect to the future activities of the Company. These
forward-looking statements by their vary nature involve risks and
uncertainties and represent the Company's judgement as of the date of
this release.
NVID International, Inc. and Aqua Bio Technologies, Inc. can be
reached at:
Corporate Office: 28870 U.S. 19 N. Suite 300
Clearwater, Florida 33761
Contact: David Larson
Phone 727/669-5005
Fax 727/669-4701
e-mail dLarson@aquabiotech.com
NVID's web site: www.aquabiotech.net
Sales Office: 5153 Sandy Cove Avenue
Sarasota, Florida 34242
Contact: Michael Redden
Phone 941/312-9100
Fax 941/312-9300
e-mail aquabiotech@home.com
--30--gaa/mi*
CONTACT: NVID International Inc., Clearwater
David Larson, 727/669-5005
E-mail: dLarson@aquabiotech.com
KEYWORD: FLORIDA INTERNATIONAL LATIN AMERICA CANADA ASIA PACIFIC
INDUSTRY KEYWORD: ENVIRONMENT CHEMICALS/PLASTICS
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
*** end of story *** |
